

Mozobil® (plerixafor)
Prior Authorization Criteria

Mozobil will be approved as a stem cell mobilizer:

1. For the treatment of non-Hodgkin's lymphoma or multiple myeloma
and
2. To be initiated after four days of treatment with granulocyte-colony stimulating factor (GCSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
3. Mozobil will not be approved when there is a diagnosis of leukemia present.
4. A maximum of 4 doses will be approved.

Genzyme Package Insert 2008

32-2004-0109

Approved 11/19/2009 DUR Board